Found 26006 clinical trials
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma
At the same time, combined with four generations of CAR-T cells and PD1 monoclonal antibody, PD1 / PDL1 signal pathway was blocked, anti-tumor effect of CAR-T was improved, and immune response and long-term remission rate of DLBCL were improved.
- 0 views
- 19 Feb, 2024
- 1 location
Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC
The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
- 0 views
- 29 Jan, 2025
- 1 location
"CHOiCE"! Choose Health: Oncological Patients Cenetered Exercise
The program considers the preferences of EX of cancer survivors, giving the possibility to choose the EX modality (autonomous, with personal trainer or group class).
- 0 views
- 19 Feb, 2024
- 2 locations
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)
(n=200) Phase 2: This is a randomized controlled trial to 1) quantify the effects of (i) physical therapy compared to (ii) a control group in individuals with AWS following breast cancer surgery related to physical activity and physical impairments such as lymphedema, shoulder motion, function, and pain (n=44, 22 in …
- 0 views
- 19 Feb, 2024
- 1 location
Clinician Communication About Sexual Health
The objective of this study is to adapt a previously tested brief intervention aimed at enhancing clinicians communication about sexual health (iSHARE) to a mobile web-based platform showcasing a two-part podcast and to assess the feasibility, acceptability, and preliminary effects of the intervention in breast cancer clinicians.
- 0 views
- 19 Feb, 2024
- 1 location
Assessing the Sensitivity of "SureTouch " in Identifying Clinically Significant Masses in Women Undergoing Diagnostic and Screening Mammography
Prospective, case-control study being conducted to determine the sensitivity of the SureTouch device in detecting known masses at a pre-determined level of specificity.
- 0 views
- 19 Feb, 2024
- 1 location
Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study
The goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with in-breast recurrences after a previous lumpectomy and RT, investigators propose to test partial breast irradiation with the target volume encompassing the entire surgical bed with 1.0-1.5 cm margins.
- 0 views
- 19 Feb, 2024
- 1 location
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer
This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB/IV Non-Squamous NSCLC harbored EGFR mutation after EGFR TKI therapy.
- 0 views
- 19 Feb, 2024
- 12 locations
Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion
The aim of the study is to evaluate the safety and feasibility of a hypofractionated, accelerated radiation approach based on the incidence of grade 3-5 NCI Common Terminology Criteria for Adverse Events (NCI-CTC-AE ) toxicity and / or termination of the planned therapy for any reason with neoadjuvant radiation with …
- 0 views
- 19 Feb, 2024
- 1 location
Consolidative Radiotherapy Versus Observation for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy
This is a phase II, multicenter, randomized open-label and comparative study designed to evaluate whether local consolidative radiotherapy improves overall survival as compared with standard management in patients with limited metastatic urothelial bladder cancer and without progression following first-line systemic therapy. Each patient will be followed during 3 years from …
- 2 views
- 19 Feb, 2024
- 12 locations